Why Choose Australia?


The USA and China IND submission pathway to initiate first-in-human clinical trials in Australia is not required, rather Australia's regulatory (TGA) body offers an efficient pathway, coupled with an streamlined ethics process, enabling biotech firms to begin trials as early as five weeks.


Australia maintains a long history of hosting the world's best researchers along with world-class research infrastructure equal to the USA.

The data generated from Australia is used to support IND and NDA regulatory filing for USA FDA. Data is also used for EMA, PMDA, and Health Canada regulatory filing.


The Australian Government's R&D Tax Incentive has made Australia an attractive R&D destination.

Companies can recover up to 43.5 cents from every dollar spent on R&D or in other words, claim 43.5% cash back on their research expenditure.